Monday, April 22, 2013
Two Abstracts Pertaining to the AE37 HER2/neu Vaccine Accepted as Poster Presentations at ASCO 2013
Two abstracts pertaining to Antigen Express' AE37 Her2/neu vaccine have been accepted for poster presentations at the 2013 American Society of Clinical Oncology ("ASCO") Annual Meeting. The annual ASCO meeting is being held in Chicago, Illinois from May 31 through June 4, 2013.
The abstract titles, with the name of the lead author, were revealed today with the launch of the meeting's iplanner. Here is the available information:
Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study.
Eleftheria A. Anastasopoulou
Risk factors for development of delayed urticarial reactions in the phase II trial of HER2 peptide vaccines plus GM-CSF versus GM-CSF alone in high-risk breast cancer patients to prevent recurrence.
Alfred F. Trappey, MD
The iplanner is available for review here.